BR112018001853A2 - métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio - Google Patents
métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbioInfo
- Publication number
- BR112018001853A2 BR112018001853A2 BR112018001853A BR112018001853A BR112018001853A2 BR 112018001853 A2 BR112018001853 A2 BR 112018001853A2 BR 112018001853 A BR112018001853 A BR 112018001853A BR 112018001853 A BR112018001853 A BR 112018001853A BR 112018001853 A2 BR112018001853 A2 BR 112018001853A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorder
- treatment
- methods
- treating
- improving
- Prior art date
Links
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 abstract 1
- 102000018511 hepcidin Human genes 0.000 abstract 1
- 229940066919 hepcidin Drugs 0.000 abstract 1
- 108060003558 hepcidin Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
Abstract
são fornecidos métodos para o tratamento de distúrbios mediados por hepcidina com base nos genótipos de tmprss6.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199434P | 2015-07-31 | 2015-07-31 | |
| US201562268788P | 2015-12-17 | 2015-12-17 | |
| PCT/US2016/044528 WO2017023699A1 (en) | 2015-07-31 | 2016-07-28 | Methods for treating hepcidin-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018001853A2 true BR112018001853A2 (pt) | 2018-09-25 |
Family
ID=57886392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018001853A BR112018001853A2 (pt) | 2015-07-31 | 2016-07-28 | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20170029499A1 (pt) |
| EP (2) | EP3329018B1 (pt) |
| JP (3) | JP2018529756A (pt) |
| KR (2) | KR20240144460A (pt) |
| CN (2) | CN108026582A (pt) |
| AU (2) | AU2016302768B2 (pt) |
| BR (1) | BR112018001853A2 (pt) |
| CA (2) | CA2991637C (pt) |
| EA (1) | EA201890185A1 (pt) |
| ES (1) | ES2877708T3 (pt) |
| HK (1) | HK1249923A1 (pt) |
| IL (2) | IL256615B (pt) |
| MX (1) | MX2018000778A (pt) |
| NZ (1) | NZ739392A (pt) |
| SG (1) | SG10201913062SA (pt) |
| TW (3) | TW202043482A (pt) |
| WO (1) | WO2017023699A1 (pt) |
| ZA (1) | ZA202003889B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | TREATMENT OF DIURETIC RESISTANCE |
| US20190241650A1 (en) * | 2018-01-05 | 2019-08-08 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
| CN111217819B (zh) * | 2018-11-27 | 2021-05-14 | 杭州科巢生物科技有限公司 | 乌帕替尼的合成方法 |
| WO2020223565A1 (en) | 2019-05-01 | 2020-11-05 | Corvidia Therapeutics, Inc. | Anti-il-6 antibody formulation |
| CN114375205A (zh) * | 2019-06-20 | 2022-04-19 | 武田药品工业株式会社 | 用基于病毒的基因疗法进行治疗的方法 |
| KR20230017204A (ko) * | 2020-04-29 | 2023-02-03 | 바이오에이지 랩스, 인코포레이티드 | 노화-관련 질환 치료용 저산소증-유도 인자 프롤릴 히드록실라제 억제제 |
| AR122933A1 (es) | 2020-07-10 | 2022-10-19 | Novo Nordisk As | Métodos para tratar la enfermedad cardiovascular |
| US20240050433A1 (en) * | 2020-12-11 | 2024-02-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Application of jak inhibitor in kidney disease |
| JP2024517931A (ja) * | 2021-05-11 | 2024-04-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｔｍｐｒｓｓ６抗体及びその使用 |
| CN113502325B (zh) * | 2021-07-02 | 2024-09-10 | 厦门市妇幼保健院(厦门市优生优育服务中心、厦门大学附属妇女儿童医院、厦门市林巧稚妇女儿童医院) | 用于孕期铁营养缺乏风险评估检测试剂盒与应用方法 |
| EP4433160A1 (en) | 2021-11-17 | 2024-09-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
| WO2023240171A1 (en) * | 2022-06-09 | 2023-12-14 | Disc Medicine, Inc. | Methods for treating blood loss conditions |
| WO2024102732A1 (en) * | 2022-11-11 | 2024-05-16 | Tourmaline Bio, Inc. | Methods for the treatment of cardiovascular disease |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856135A (en) | 1993-05-31 | 1999-01-05 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human antibody to human interleukin-6 |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| DK1562968T3 (da) | 2001-11-14 | 2013-10-28 | Janssen Biotech Inc | Anti-il-6-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
| US20060275294A1 (en) * | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078532A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078533A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| EP1536012A4 (en) | 2002-08-30 | 2006-03-08 | Chemo Sero Therapeut Res Inst | HUMAN-TYPE ANTIHUMAN INTERLEUKIN-6 ANTIBODY ANTIBODY ANTIBODY FRAGMENT |
| WO2005028514A1 (en) * | 2003-09-22 | 2005-03-31 | Biovation Gmbh & Co. Kg. | Use of a compound for reducing the biological effectiveness of il-6 |
| WO2005080429A2 (en) | 2004-02-11 | 2005-09-01 | Warner-Lambert Company Llc | Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies |
| JO3058B1 (ar) | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
| KR101414438B1 (ko) | 2005-05-20 | 2014-07-10 | 아블린쓰 엔.브이. | 폰 빌레브란트 인자에 대한 단일 도메인 ｖｈｈ 항체 |
| US7820790B2 (en) * | 2005-07-13 | 2010-10-26 | Amgen Mountain View Inc. | IL-6 binding proteins |
| RU2450830C2 (ru) * | 2005-10-21 | 2012-05-20 | Чугаи Сейяку Кабусики Кайся | Средства для лечения кардиопатии |
| CA2657763C (en) | 2006-08-03 | 2016-05-31 | Vaccinex Inc. | Anti-il-6 monoclonal antibodies and uses thereof |
| TW200831528A (en) * | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| CA2676036A1 (en) * | 2007-02-02 | 2008-08-14 | Amgen Inc. | Hepcidin, hepcidin antagonists and methods of use |
| US8404235B2 (en) * | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US9884899B2 (en) * | 2007-07-06 | 2018-02-06 | Promedior, Inc. | Methods for treating fibrosis using CRP antagonists |
| US8034344B2 (en) | 2008-05-13 | 2011-10-11 | Novimmune S.A. | Anti-IL-6/IL-6R antibodies and methods of use thereof |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| DK3338799T3 (da) * | 2008-11-25 | 2021-06-14 | Vitaeris Inc | Antistoffer til il-6 og anvendelse deraf |
| KR20110108398A (ko) | 2009-01-29 | 2011-10-05 | 메디뮨 엘엘씨 | 연장된 생체내 반감기를 갖는 인간 안티-ｉｌ-6 항체 및 종양학, 자가면역 질환 및 염증성 질환의 치료에 있어서의 이들의 용도 |
| KR101709492B1 (ko) * | 2009-03-18 | 2017-02-23 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| MX342810B (es) | 2011-03-03 | 2016-10-13 | Apexigen Inc | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. |
| FR2978964B1 (fr) * | 2011-08-09 | 2015-02-20 | Conservatoire Nat Arts | Composition vaccinale anti-il-6 |
| WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
| JP2015536934A (ja) * | 2012-10-25 | 2015-12-24 | メディミューン，エルエルシー | 安定した低粘度の抗体製剤 |
| RU2670943C9 (ru) | 2012-11-08 | 2018-11-26 | Илэвэн Байотерапьютикс, Инк. | Антагонисты ил-6 и их применение |
| MX2015005839A (es) * | 2012-11-08 | 2015-12-17 | Clearside Biomedical Inc | Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| ES2695166T3 (es) | 2013-03-15 | 2019-01-02 | Intrinsic Lifesciences Llc | Anticuerpos antihepcidina y usos de los mismos |
| US20160130340A1 (en) | 2013-10-07 | 2016-05-12 | Alderbio Holdings Llc | Dosing regimens using anti-il-6 antibodies for the treatment of rheumatoid and psoriatic arthritis |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| UY36449A (es) | 2014-12-19 | 2016-07-29 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a bmp6 |
| EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | TREATMENT OF DIURETIC RESISTANCE |
-
2016
- 2016-07-28 CA CA2991637A patent/CA2991637C/en active Active
- 2016-07-28 EP EP16833574.3A patent/EP3329018B1/en active Active
- 2016-07-28 SG SG10201913062SA patent/SG10201913062SA/en unknown
- 2016-07-28 BR BR112018001853A patent/BR112018001853A2/pt not_active Application Discontinuation
- 2016-07-28 AU AU2016302768A patent/AU2016302768B2/en active Active
- 2016-07-28 ES ES16833574T patent/ES2877708T3/es active Active
- 2016-07-28 US US15/222,507 patent/US20170029499A1/en not_active Abandoned
- 2016-07-28 EP EP21157575.8A patent/EP3888752A1/en active Pending
- 2016-07-28 CN CN201680045105.6A patent/CN108026582A/zh active Pending
- 2016-07-28 JP JP2018525517A patent/JP2018529756A/ja active Pending
- 2016-07-28 CN CN202110454211.2A patent/CN113117074A/zh active Pending
- 2016-07-28 CA CA3119498A patent/CA3119498A1/en active Pending
- 2016-07-28 MX MX2018000778A patent/MX2018000778A/es unknown
- 2016-07-28 WO PCT/US2016/044528 patent/WO2017023699A1/en active Application Filing
- 2016-07-28 KR KR1020247031313A patent/KR20240144460A/ko not_active Application Discontinuation
- 2016-07-28 KR KR1020187005991A patent/KR102709681B1/ko not_active Application Discontinuation
- 2016-07-28 NZ NZ73939216A patent/NZ739392A/en unknown
- 2016-07-28 EA EA201890185A patent/EA201890185A1/ru unknown
- 2016-07-29 TW TW109105227A patent/TW202043482A/zh unknown
- 2016-07-29 TW TW107134726A patent/TWI778140B/zh active
- 2016-07-29 TW TW105124201A patent/TWI653339B/zh active
-
2017
- 2017-12-27 IL IL256615A patent/IL256615B/en active IP Right Grant
-
2018
- 2018-07-19 HK HK18109361.2A patent/HK1249923A1/zh unknown
-
2019
- 2019-11-19 AU AU2019268074A patent/AU2019268074B9/en active Active
-
2020
- 2020-06-26 ZA ZA2020/03889A patent/ZA202003889B/en unknown
- 2020-12-09 IL IL279308A patent/IL279308A/en unknown
-
2021
- 2021-03-09 US US17/195,757 patent/US20210292405A1/en active Pending
- 2021-12-07 JP JP2021198768A patent/JP7386838B2/ja active Active
-
2023
- 2023-09-15 JP JP2023150185A patent/JP2023169297A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
| BR112019006160A2 (pt) | composições e métodos para o tratamento das condições oftálmicas | |
| ECSP17073743A (es) | Moduladores de k-ras | |
| MX2017008844A (es) | Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico. | |
| BR112017002332A2 (pt) | terapia de combinação para o tratamento de um paramixovírus | |
| BR112017007902A2 (pt) | composições e métodos para o tratamento de distúrbios do sistema nervoso central. | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| BR112017006664A2 (pt) | terapias de combinação | |
| BR112018011709A2 (pt) | inibidores bicíclicos de pad4 | |
| CO2017004314A2 (es) | Compuestos anti-tnf | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| BR112019002331A2 (pt) | anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| BR112015023207A8 (pt) | composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase. | |
| EA201991818A1 (ru) | Лечение рака | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| BR112016026544A2 (pt) | métodos para inibir a necroptose | |
| BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
| EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
| BR112018070497A2 (pt) | métodos e formulações farmacêuticas para tratamento de condições oculares | |
| IL271728A (en) | Materials, uses and treatment methods | |
| MX2017015311A (es) | Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer. | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| CO2017002356A2 (es) | Métodos para tratar la depresión usando moduladores de nmda |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B25A | Requested transfer of rights approved |
Owner name: MEDIMMUNE LIMITED (GB) ; ASTRAZENECA UK LIMITED (GB) |
|
| B25A | Requested transfer of rights approved |
Owner name: MEDIMMUNE LIMITED (GB) ; ASTRAZENECA AB (SE) |
|
| B25A | Requested transfer of rights approved |
Owner name: MEDIMMUNE LIMITED (GB) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024015806-0 PROTOCOLO 870240065235 EM 01/08/2024 14:09.O PEDIDO FOI DIVIDIDO NO BR122024015811-6 PROTOCOLO 870240065254 EM 01/08/2024 14:27. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |